ASD behavior management success related to using the AVACEN 100 has been reported for years by parents who initially purchased the device for themselves and then had their ASD children try it. Improvements range from speech impediments quickly disappearing, to increased classroom participation and enthusiastic homework completion. These encouraging developments have also been accompanied by school grades skyrocketing from D’s to A’s and B’s in just a few months.
According to Gavin Wiswell, a Healthcare Executive from San Marcos California, “Within the first two weeks of using the AVACEN 100 device for 30 minutes, twice a day, my 6-year-old son shocked us by reading a children’s book that he had never read before; from cover to cover, out loud, using his finger to point and perfectly pronounce each word. He typically would recite them back to us from memory, so this was a major breakthrough for our son!”
With approximately 3 million treatments and zero reported adverse effects, the AVACEN 100 is the only known medical device able to safely and noninvasively warm the body rapidly by infusing into the circulatory system using the palm of the hand.
The AVACEN 100 mechanism of action has been thought to mimic the effects of a moderate fever. For over 30 years moderate fever has been recognized as a catalyst for normalizing ASD children for days or even weeks [1] [2]. The Company believes this explains why using the AVACEN 100 daily has been observed to produce in continuous normalization of certain aspects of ASD behavior.
About AVACEN 100 Patents
The US Patent Office has issued 4 Patents to AVACEN. The patents cover innovations embodied in the AVACEN 100 system, which is expected to allow multiple therapeutic uses to alleviate symptoms associated with a circulatory, neurological, lymphatic, or endocrinal dysfunction, or any combination thereof. Patents have also been issued for China, Australia, Japan, UK, France, Germany, Spain, Sweden and Canada. Patents are pending in other countries.
Bill Sickert 